Litcius/Paper detail

Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?

Milton Packer

2023Nature Cardiovascular Research14 citationsDOI

Topics & Concepts

Food and drug administrationClinical trialMedicineLandmarkDual (grammatical number)Drug approvalDrugInternal medicinePharmacologyComputer scienceArtificial intelligenceLiteratureArtDiabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes Management and Research